Recently, the launching ceremony of the "2024 Guangzhou Private Enterprise Service Week" was grandly held at the Baiyun International Conference Center in Guangzhou. The event was jointly hosted by the United Front Work Department of the CPC Guangzhou Municipal Committee, the Guangzhou Municipal Bureau of Industry and Information Technology, and the Guangzhou Federation of Industry and Commerce. Guangzhou's Vice Mayor Jiang Zhitao attended the ceremony and delivered a speech.
During the event, Vice Mayor Jiang Zhitao, together with Wang Shitong, a member of the Standing Committee of the Guangzhou Municipal Committee and Minister of the United Front Work Department, presented the plaque to representatives of the sixth batch of national-level "Specialized, Refined, Characteristic, and Innovative" (Little Giant) enterprises in Guangzhou. Guangzhou Fuda Medical Co., Ltd., as one of the representatives from Haizhu District, was honored with this title.
Founded in 2016, Guangzhou Fuda Medical Co., Ltd. was recognized as a "High-Tech Enterprise" and became a National Clinical Key Specialty (Oncology) hospital in May 2018. The company has steadily advanced along its development path, placing a strong emphasis on discipline construction and scientific research innovation. With its focus on minimally invasive ablation technologies such as the Nanoknife and cryoablation, Fuda Medical has acquired 12 Class I intellectual property rights, 16 Class II intellectual property rights, one self-established enterprise technology center, and one national clinical trial base. The company has conducted or completed three national-level scientific projects, two provincial-level technology projects, 14 municipal-level projects, and 61 independent R&D projects. It has published 415 academic papers on the research and development of its leading products in the field of oncology.
Among its achievements, the Nanoknife technology has been successfully applied to over 1,000 cases of pancreatic and liver cancer, significantly improving the quality of life for patients. In addition to its domestic applications, the "Triple-Cycle Cryoablation Therapy" has also been recognized and adopted by international medical peers. These accomplishments confirm Fuda Medical’s leadership position in the field of oncology treatment.
The recent recognition as a national-level "Specialized, Refined, Characteristic, and Innovative" (Little Giant) enterprise marks Fuda Medical as a pioneer with strong innovation capabilities and core technologies, characterized by professionalism, precision, and novelty. This honor not only acknowledges Fuda Medical's dedication to the healthcare field over the past two decades but also sets expectations for the company to continue leading industry innovation and implementing the Health China Strategy in the future.